Allergic rhinitis is the most common atopic disorder seen in the outpatient clinic. Montelukast, is a novel medication, is an antagonist to the leukotriene receptor. The aim of this work was to identify the improvement in the severity of symptoms of child with AR treated with Montelukast. A cross-sectional study was conducted among fifty-patients with a chronic cough and (sneezing, nasal congestion, rhinorrhea, and postnasal drip) at least eight weeks using Montelukast between the periods of January 2019 to March 2019. By using the symptom severity score for AR, that calculated. Data including (age, gender, associated disease, exacerbation factors, and classical therapy). The dose of 10-mg Montelukast once daily was prescribed. On follow-up, after four-weeks, compliance was ensured and then the symptom severity score was recorded again. Most of patients aged above 40 years. Males to females ratio was 1:1.5. Most of patients (40, 80%) lived in urban regions. There was a reduction of the symptoms associated with RA after treatment with Montelukast.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.